title: Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells.
abstract: The effect of 15 antiphospholipid antibody (APA) positive SLE sera, 13 APA negative SLE sera, 10 APA negative sera from patients with other connective tissue diseases (CTD) and 15 control sera on the expression of endothelial procoagulant activity (PCA) was studied. Endothelial cells (EC) were stimulated with tumor necrosis factor (TNF) and 20% serum for 4 hr and the surface PCA expression was measured. Without TNF, none of the sera stimulated PCA expression. With suboptimal TNF stimulation, 14/15 APA positive SLE sera, 7/13 APA negative SLE sera, 2/10 CTD sera and 2/15 control sera enhanced PCA expression. This stimulating effect resided in the IgG fraction and was associated with the presence of APA, but not with a history of thrombosis. Purified APA had no PCA stimulating activity. PCA expression was inhibited by cycloheximide and heat treatment (30 min, 56 degrees C) of serum. In conclusion, 21/28 (75%) SLE sera increase the TNF-induced endothelial PCA expression. Although this effect predominantly occurs with APA positive serum, a causative role of APA was not demonstrated.
authors.affiliation: Department of Haematology, University Hospital Utrecht, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Hasselaar
authors.forename: R H
authors.initials: RH
authors.lastname: Derksen
authors.forename: J D
authors.initials: JD
authors.lastname: Oosting
authors.forename: L
authors.initials: L
authors.lastname: Blokzijl
authors.forename: P G
authors.initials: PG
authors.lastname: de Groot
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000302:isolation & purification / Q000502:physiology; D001779:Blood Coagulation Factors / Q000096:biosynthesis* / Q000276:immunology / Q000502:physiology; D001780:Blood Coagulation Tests; D002308:Cardiolipins / Q000276:immunology; D002478:Cells, Cultured; D002863:Chromogenic Compounds; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000302:isolation & purification; D016682:Lupus Coagulation Inhibitor; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D001323:Autoantibodies; D001779:Blood Coagulation Factors; D002308:Cardiolipins; D002863:Chromogenic Compounds; D007074:Immunoglobulin G; D016682:Lupus Coagulation Inhibitor; D014409:Tumor Necrosis Factor-alpha